Roche pledges nearly $300M to establish new Vabysmo production plant in China
Roche is investing roughly $282 million to erect a new biomanufacturing hub in Shanghai. The plant, which will mark Roche’s second for branded medicines in the country, will mainly be used for domestic production of the eye med Vabysmo.,
Roche is investing roughly $282 million to erect a new biomanufacturing hub in Shanghai. The plant, which will mark Roche’s second for branded medicines in the country, will mainly be used for domestic production of the eye med Vabysmo.,
